# The BINACLE (binding and cleavage) assay for *in vitro* activity determination of tetanus neurotoxin

Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel Federal Institute for Vaccines and Biomedicines



Das Paul-Ehrlich-Institut ist ein Bundesinstitut im Geschäftsbereich des Bundesministeriums für Gesundheit. The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health.



Heike Behrensdorf-Nicol Research Scientist E-mail: Heike.Behrensdorf-Nicol@pei.de



# Disclaimer

The views expressed in this presentation are the personal views of the presenter. They shall not be understood or cited as opinions of the Paul-Ehrlich-Institut. The presenter has not received any funding or grants from companies or from associations representing companies.

The reproduction and distribution of information and data from this presentation (text, image, graphics) is prohibited without the prior written consent of the presenter and the Media and Public Relations Unit at the Paul-Ehrlich-Institut (presse@pei.de). This also applies to the reproduction and distribution of excerpts from the presentation. No liability for the topicality and completeness of the information provided will be assumed.



## Paul-Ehrlich-Institut: Health is at the heart of our work



- Federal higher authority based in Langen near Frankfurt am Main in the heart of Germany and Europe.
- We contribute to the
- QUALITY, SAFETY and EFFICACY as well as - the AVAILABILITY
- of vaccines and biomedicines.
- We test and evaluate vaccines and biomedicines, approve clinical trials in Germany and grant marketing authorisations.
- Our research focuses on model drugs and method development.
- ZEPAI represents our responsibility for planning and implementing pandemic preparedness and pandemic response measures with pandemic vaccines and therapeutics.
- Our expertise allows us to support groups such as medicines developers and manufacturers by providing regulatory scientific advice along the entire drug life cvcle.
- We collect and evaluate incidents pertaining to certain in vitro diagnostic medical devices (e.g. CoV-2 rapid antigen tests) and approve performance studies.



# INTRODUCTION: TETANUS NEUROTOXIN AND THE BINACLE ASSAY



### Tetanus neurotoxin

### Tetanus neurotoxin (TeNT) produced by Clostridium tetani

- Targets inhibitory interneurons → Muscle spasms, asphyxiation
- Extremely potent (lethal dose for humans + many animals: ~1-10 ng/kg body weight)

#### Chemically inactivated TeNT (tetanus toxoid) is used as vaccine

- Each bulk must be tested for absence of active TeNT
- Due to high toxicity: Reliable method for toxin detection needed

European Pharmacopoeia: Test for "Absence of tetanus toxin" (veterinary + human vaccines)

- Toxoid injected into 5 guinea pigs, 21 days observation phase
- No animal should show tetanus symptoms
- No generally accepted alternative method to date





# Reasons for developing in vitro methods


#### Disadvantages of in vivo test:

- Ethical concerns
- High variability + low precision
- Guinea pig test was introduced decades ago
  - → poorly standardised, not properly validated (e.g. detection limit unknown)
- Long duration (3 weeks observation phase)
- Expensive (animal facilities)


#### → Replacement by *in vitro* method preferable




# Mode of action of TeNT




- 1.  $H_C$  binds receptor on neuron
- 2. H<sub>N</sub> forms transmembrane channel





Paul-Ehrlich-Institut 鱗

# Single assays (binding assay / endopeptidase assay)



[Figure from: Behrensdorf-Nicol HA, Bonifas U, Kegel B, Silberbach K, Krämer B, Weißer K (2010) Toxicology In Vitro 24:988-994] Toxoids (various manufacturers) tested in


(A) receptor-binding assay(B) assay for synaptobrevin-cleaving activity

- All toxoids showed high signals already at concentrations <10 Lf/ml</li>
- Signals do not correspond to *in vivo* toxicity (all toxoids had passed the animal test)


→ Single assays: No reliable discrimination between active toxin and inactivated toxoid molecules




# **BINACLE** assay principle



. Plate coated with receptor: Binding and reduction






[Figure adapted from: Behrensdorf-Nicol H, Weisser K, Krämer B (2015), ALTEX 32:41-46]

### BINACLE (binding and cleavage) assay for *in vitro* activity determination

- mimics key steps of TeNT mode of action: Receptor binding + synaptobrevin cleavage
- detects active TeNT molecules based on several characteristic features:
  - functional binding domain (H-chain) + functional protease domain (L-chain)
  - both chains must be separable by reduction



# BINACLE assay allows TeNT detection in toxoids



[Figure from: Behrensdorf-Nicol H, Le Tallec D, Sinitskaya N, Behr-Gross ME, Göngrich C (2024) Pharmeur Bio Sci Notes 2024:162-192]

### **BINACLE** assay:

- Non-spiked toxoid Signals did not exceed blank value even when tested at high concentration (500 Lf/ml)
- Toxoid spiked with TeNT: Clear dose-responserelationship, sensitive TeNT detection
- → Strongly improved discrimination between active toxin and inactivated toxoid molecules compared to single assays
  (Note: Some toxoids may not be suitable for BINACLE testing; toxoids from some sources induce elevated background signals.)



# COLLABORATIVE STUDY BSP 136



# Collaborative study for TeNT BINACLE assay


### International collaborative study (BSP 136):

- Organised by EDQM (European Directorate for the Quality of Medicines & HealthCare)
- In the context of the Biological Standardisation Programme
- Participants: Vaccine manufacturers, national control laboratories
- Detailed assay protocol + critical reagents were supplied to participants
- Test samples: TeNT diluted in tetanus toxoids (to mimic insufficiently inactivated toxoid)
- Each participant performed 3 to 4 BINACLE tests

### →Aim: Characterise applicability of BINACLE assay for toxicity testing of tetanus toxoids



### Collaborative study, part 1



[Figure from: Behrensdorf-Nicol H, Krämer B, Le Tallec D, Sinitskaya N, Behr-Gross ME (2024) Pharmeur Bio Sci Notes 2024:127-161]


**Results of study part 1** (19 participants):

- Most participants obtained clear dose-response curves
- But: High variability
  - 7 laboratories: Sensitive TeNT detection (≤0.5 ng/mL)
  - − 4 laboratories: Unable to detect even 5 ng/mL TeNT X
- → Based on these data, improvements were introduced to reduce variability and enhance standardisation
  - Protocol optimisation
  - More pre-qualified reagents

#### → Improved BINACLE assay tested in study part 2



## Collaborative study, part 2



[Figure from: Behrensdorf-Nicol H, Le Tallec D, Sinitskaya N, Behr-Gross ME, Göngrich C (2024) Pharmeur Bio Sci Notes 2024:162-192]

Results of study part 2 (9 participants):

- All participants obtained clear dose-response curves
- Detection limit calculated by cut-off-based method:

*cut-off = mean blank value + 3.3 x standard deviation* 

- all laboratories were able to detect 0.33 ng/mL TeNT
- 5 laboratories were able to detect 0.11 ng/mL TeNT
- → Detection limit of BINACLE assay: in same range as the estimated detection limit of the animal test



### Collaborative study, part 2 (continued)

**Variability**\* (indicated as geometric coefficients of variation):

Intra-laboratory variability (average)	12 %
Inter-laboratory variability	4 %
Reproducibility (intra- + inter-laboratory variability)	13 %

(\* calculated by ANOVA based on relative potency values determined for TeNT in toxoid relative to TeNT in buffer)

### → Variability is similar to commonly reported values for immunochemical assays



# CONCLUSION AND OUTLOOK



# Conclusion

- Optimised BINACLE assay allows reliable detection of active TeNT
  - Transferability: All participants successfully performed the method •
  - Detection limit: Equivalent to estimated detection limit of in vivo test •
  - Variability: Acceptable for a multi-step assay •
- Note: BINACLE assay may not be applicable to all toxoids, toxoids from some sources induce high background signals
- For suitable tetanus toxoids, the BINACLE assay may represent a good alternative to the safety test in guinea pigs



## Outlook

- Discussions about inclusion of the BINACLE assay into the European Pharmacopoeia as alternative to the guinea pig test for 'Absence of tetanus toxin' are underway
- Before the method can be used for batch testing purposes, users need to validate it for their specific toxoid product

Key point: It must be shown that **non-compliant bulks** are **reliably detected** → to make sure that the **switch to** *in vitro* **testing** has no negative impact, but rather **contributes to high product quality + safety** 

Webinar on TeNT BINACLE assay: 12 November 2024 (organised by EDQM)
→ for more information, see <u>www.edqm.eu</u>, Events & training



### Acknowledgements

#### **Project team at Paul-Ehrlich-Institut:**

Ursula Bonifas, Jolanta Klimek, Beate Krämer, Birgit Kegel, Karin Weißer, Emina Wild, Kay-Martin Hanschmann



**EDQM** (European Directorate for the Quality of Medicines & HealthCare, Strasbourg, France):

Thanks for organizing the collaborative study BSP 136 to Christina Göngrich, Marie-Emmanuelle Behr-Gross, Sally Woodward, David LeTallec, Natalia Sinitskaya





EUROPEAN UNION



CONSEIL DE L'EUROPE

Co-funded and implemented by the Council of Europe





Federal Ministry of Education and Research









08.10.2024



Das Paul-Ehrlich-Institut ist ein Bundesinstitut im Geschäftsbereich des Bundesministeriums für Gesundheit. *The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health.* 



# THANK YOU VERY MUCH FOR YOUR ATTENTION